Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study
暂无分享,去创建一个
A. Kaser | O. Dewit | G. D'Haens | M. Ferrante | F. Baert | B. Feagan | J. Panés | E. Louis | Kori L Wallace | Yinuo Pang | Wan-Ju Lee | Kori L. Wallace | W. Duan | J. Kalabic | X. Liao | D. Gustafson | Wan‐Ju Lee
[1] A. Othman,et al. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients , 2019, Clinical Pharmacokinetics.
[2] L. Stassen,et al. ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.
[3] A. Othman,et al. Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients , 2019, Clinical pharmacology and therapeutics.
[4] E. H. Thompson,et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial , 2019, The Lancet.
[5] B. Strober,et al. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs , 2019, Drug Safety.
[6] A. Kaser,et al. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. , 2018, The lancet. Gastroenterology & hepatology.
[7] A. Othman,et al. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials , 2018, Clinical Pharmacokinetics.
[8] E. H. Thompson,et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials , 2018, The Lancet.
[9] P. Mease,et al. OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial , 2018, FRIDAY, 15 JUNE 2018.
[10] S. Targan,et al. Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy , 2018, Alimentary pharmacology & therapeutics.
[11] M. Regueiro,et al. ACG Clinical Guideline: Management of Crohn’s Disease in Adults , 2018, The American Journal of Gastroenterology.
[12] Nima Hamidi,et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.
[13] A. Kaser,et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study , 2017, The Lancet.
[14] S. Ng,et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. , 2013, Gastroenterology.
[15] H. Tilg,et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management , 2017, Journal of Crohn's & colitis.
[16] P. Rutgeerts,et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.